Read the RTZ-GLP4 Research Pathway Chart. Review the research context and evidence limitations.
RTZ-GLP4, a custom SRP research blend
RTZ-GLP4 contains 10 mg GLP3-Reta (retatrutide) and 2 mg PEG-MGF per vial, 12 mg total. SRP developed this custom formula for laboratory investigations at the intersection of metabolic signaling and growth-factor-associated tissue-response research.
Formula breakdown
| Component | Amount per vial |
|---|---|
| GLP3-Reta / retatrutide | 10 mg |
| PEG-MGF | 2 mg |
| Total blend | 12 mg |
Multi-incretin research
Retatrutide is a single molecule investigated for activity at GLP-1, GIP and glucagon receptors. Published research on retatrutide helps frame questions about metabolic signaling. Those studies did not evaluate this SRP blend.
Growth-factor-associated research
PEG-MGF is a modified peptide associated with mechano-growth-factor research. Native MGF studies provide background for tissue-response questions, but cannot establish the behavior of a PEG-modified product or this combined formulation. Formulation-specific mechanism, stability and biological activity require direct investigation.
What researchers can investigate
- Identity and content of each component using validated methods.
- Blend compatibility, degradation and storage stability.
- Receptor signaling and cellular responses in suitable controlled models.
- Differences between each ingredient alone and the finished blend.
Understanding the name
RTZ-GLP4 is an SRP product name. It does not mean a fourth incretin receptor, a quadruple receptor agonist, or a clinically validated next generation treatment. GLP-2 is a distinct biological hormone, not a product generation.
Documentation and evidence
Review batch-specific documentation when available and match it to the supplied lot. No study of this exact combination is cited here. Ingredient research does not demonstrate combined benefits, synergy, safety or effectiveness. No batch-specific purity or sterility claim is made on this page.
How it works: research pathway map
Research references
- Retatrutide phase 2 research, PMID 37366315, retatrutide alone, not this blend.
- MGF delivery research, PMID 24908137, native MGF in a hydrogel system, not PEG-MGF or this blend.
Research use only
Sold strictly for laboratory research. Not for human or veterinary use, consumption, medical or diagnostic use, treatment, weight loss, appetite control or diabetes management. No administration or dosing instructions are provided.
Reviews
There are no reviews yet.